奥赛康：子公司在2025年ASCO GI发布创新药ASKB589治疗一线晚期胃癌研究成果

Core Viewpoint - The announcement highlights the promising results of the clinical study for ASKGENE LIMITED's innovative drug ASKB589, which targets CLDN18.2 in combination with CAPOX and PD-1 inhibitors for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma [1] Group 1: Clinical Study Results - ASKB589 combined with CAPOX and PD-1 inhibitors showed significant tumor response and sustained survival benefits in the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma [1] - The combination therapy demonstrated good tolerability, with no additional safety risks observed from the inclusion of PD-1 inhibitors [1] Group 2: Future Research Directions - The results support the initiation of a Phase III clinical trial targeting patients with CLDN18.2 high expression in stage IV gastric/gastroesophageal junction adenocarcinoma for the ASKB589 triple therapy [1]